bilaterals.org logo
bilaterals.org logo

medicines

ICAAP10 2011: No safe avenue to address your concerns
29-Aug-2011 HealthDev.Net
The 10th International Conference on AIDS in Asia and the Pacific (ICAAP10) has been turned upside down completely
Protestors attacked by police at international AIDS conference
29-Aug-2011 The Scavenger
An anti-Free Trade Agreement protest that took place outside an International Congress on AIDS in the Asia Pacific (ICAAP) in Busan, South Korea, on 27 August was violently attacked by police.
House legislators lobby to exclude 12-year data exclusivity period from free trade agreement
12-Aug-2011 Patent Docs
Last week, a group of seven House Democrats, led by Rep. Henry Waxman (D-CA), sought to have the 12-year data exclusivity period provided by the biosimilar approval pathway of the US’ Patient Protection and Affordable Care Act excluded from the Trans-Pacific Partnership agreement
DoP to convey concerns of industry over proposed FTAs, TPPA to commerce ministry
10-Aug-2011 PharmaBiz
India’s Department of Pharmaceuticals will take up issues with the Commerce Ministry regarding the proposed Trans Pacific Partnership Agreement which is likely to have adverse impact on the Indian pharma products, and other such Free Trade Agreements in the pipeline.
A trade barrier to defeating AIDS
27-Jul-2011 NY Times
The new strategy is to treat people in Egypt, Paraguay, Turkmenistan or China — middle-income countries, all — as if they or their governments could pay hundreds or even thousands of dollars a year each for AIDS drugs.
Impact Assessment of CETA IPR chapter
25-Jul-2011 ULB
CETA IPR chapter will likely have a slight positive effect on specific industries in the EU, such as agri-food companies using geographical indications. It would also benefit the Canadian publishing industry and the innovative pharmaceutical industry. At the same time, an IPR chapter in CETA could lead to notable negative effects in Canada, for example via higher prices on educational and pharmaceutical products.
SOCMA offers support for free trade pacts with South Korea, Panama, and Colombia
17-Jul-2011
The Society of Chemical Manufacturers and Affiliates (SOCMA) issued its support this week of the passage of pending free-trade agreements (FTA) with South Korea, Panama and Colombia by two Congressional committees. SOCMA is the US-based trade association representing custom and batch manufacturers, including contract manufacturers of fine chemicals, pharmaceutical intermediates, and active pharmaceutical ingredients.
EU-India FTA - the data exclusivity dilemma
15-Jul-2011 Public Service Europe
Conflict between European and Indian pharma industries might be played out again in FTAs with other nations
"BRICS can ensure affordable drugs"
10-Jul-2011
While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over.
Korea-EU FTA to put Seoul at public health crossroads
8-Jul-2011
Pharmaceuticals might not have been the most discussed sector before the Korea-European Union Free Trade Agreement came into effect from July 1.
Millions will die if India stops AIDS drugs — UN
6-Jul-2011 Reuters
Millions of people dependent on life-saving generic drugs to treat HIV/AIDS will die if India stops producing cheap drugs for the disease due to its trade deal with the European Union, the head of UNAIDS warned on Tuesday.
ACT UP-Paris wakes up the European Commissioner for Trade in Belgium
3-Jul-2011 ACT UP-Paris
This morning, in a small town in the region of Gent, Belgium, activists from Act Up-Paris woke up the European Commissioner for Trade in front of his house. They unfurled a banner which said ‘De Gucht, AIDS accomplice’.
5 WikiLeaks revelations exposing the rapidly growing corporatism dominating American diplomacy abroad
27-Jun-2011 Alternet
One of WikiLeaks’ greatest achievements has been to expose the exorbitant amount of influence that multinational corporations have over Washington’s diplomacy.
US breaks UN AIDS summit commitment on access to treatment
27-Jun-2011
The Asia Pacific Network of Positive People (APN+) is expressing outrage at ongoing free trade agreement negotiations by the United States with Vietnam and Malaysia that threaten access to medicines for HIV, TB, hepatitis-C as well as other diseases in these countries.
The Bangkok Declaration on free trade agreements & access to medicines
23-Jun-2011
Statement of May 2011 against the increasingly rapid spread of Free Trade Agreements that put the profits of multinational pharmaceutical companies ahead of people’s right to health around the world.
India says ‘no’ to policy that would block access to affordable medicines
23-Jun-2011 MSF
India formally announced at the UN High Level Meeting on HIV and AIDS that it will not accept data exclusivity, a provision harmful to access to affordable medicines, as part of a free trade agreement currently being negotiated with the European Union.
Shape of US TPP pharmaceuticals chapter emerges
16-Jun-2011 Infojustice
The TPP chapter may be best seen as a significant step toward the pharmaceutical industry’s ultimate goal, which is a binding international agreement on drug pricing that would restrain the ability of governments to use collective purchasing power to demand prices below “market” levels.
Pharmac trade row heralds wider threat
9-Jun-2011
Pharmac is being targeted by US drug companies as trade negotiations continue with the United States.
Health groups call for moratorium on FTAs, TRIPS-plus measures by developed nations
8-Jun-2011 PharmaBiz
As the global community meets in New York for the United Nations General Assembly High Level Meeting on HIV and AIDS from 8 to 10 June 2011, networks of People living with HIV, health groups and treatment activists from around the world are calling for an immediate moratorium on all Free Trade Agreements (FTAs) and TRIPS-plus measures.
Wrestling with Big Pharma
2-Jun-2011
Canadians spend a lot of money (public and private) on health care and much of that is spent on drugs — some $23.4 billion in 2008. Provincial insurance plans are desperately trying to cope, looking to initiatives like the recently passed Ontario law that caps prices of generic drugs at 25 per cent of the brand name equivalent.